



# **Karisma Core variables**

## **Version History**

Version	Date	Comments
1.0	2020-06-23	Initial version
1.1	2021-02-23	Add new variables: cbirads_0m, cbirads_6m, cbirads_exit

The Karisma core variables are central variables picked from the entire Karisma data collection and refer to the date at baseline, i.e. first assessment in Karisma, if not stated otherwise. Karisma holds the following core variables.

# **Demographics**

studieid ID of person in study

age\_studyentry Age at assessment. First date of survey interview and

blood drawing.

dateofbirth Date of birth.

started time Baseline survey started time for response.

finished\_time Baseline survey finish time for complete response.

rand\_group Randomization group

randomization nr Randomization number

firstpill\_date Date of the first pill

(Variables at the time of baseline)

visitdate 0m Entry date of the woman in the study, first date of the

survey and blood drawing.

bmi\_0m Body Mass Index at study entry

length\_0m Length in cm at study entry weight 0m Weight in kg at study entry

bloodpressure\_systolic\_0m Systolic blood pressure at study entry

imp\_out\_0m Number of pills out at study entry

survey\_status\_0m Baseline survey status:

0 = not answered, 1 = complete, 2 = incomplete

(Variables at 1 month)

survey\_status\_1m Follow-up survey status at 1 month:

0 = not answered, 1 = complete, 2 = incomplete

(Variables at 3 months)

survey\_status\_3m Follow-up survey status at 3 months:

0 = not answered, 1 = complete, 2 = incomplete

(Variables at 6 months)

visitdate 6m Visit date at 6 months

bmi\_6m Body Mass Index at 6 months

length\_6m Length in cm at 6 months weight 6m Weight in kg at 6 months

imp\_in\_6m Number of returned pills out at 6 months

imp\_in\_forgot\_6m Forgot to bring remaining pills at 6 months

survey\_status\_6m Follow-up survey status at 6 months:

0 = not answered, 1 = complete, 2 = incomplete

(Variables at 12 months)

visitdate 12m Visit date at 12 months

bmi 12m Body Mass Index at 12 months

length\_12m Length in cm at 12 months weight 12m Weight in kg at 12 months

survey\_status\_12m Follow-up survey status at 12 months:

0 = not answered, 1 = complete, 2 = incomplete

## **Study Interruption**

interrupt\_cause Cause of study interruption:

100 = the participant wishes to interrupt her

participation in the study

200 = Unacceptable side effects

300 = Interrupt due to violation to protocol

400 = Severe adverse events (SAE).

imp\_stop\_decision Decision to interrupt study:

1 = PI decision

2 = Participant's decision.

interrupt\_date Date of study interruption

imp stop date Date of stop taking pills

study\_stop Stop study participation

#### (Variables at date of exit examination)

visitdate\_exit Visit date at exit examination

bmi\_exit Body Mass Index at date of exit examination

length\_exit Length in cm at date of exit examination

weight\_exit Weight in kg at date of exit examination

survey status exit Follow-up survey status at date of exit examination:

0 = not answered, 1 = complete, 2 = incomplete

imp\_in\_exit Number of returned pills out at date of exit

examination

imp\_in\_forgot\_exit Forgot to bring remaining pills at date of exit

examination

### Medication

(Survey based variable at baseline in Karisma)

painkillers Use of OTC painkillers in last year. See question sb9 in

questionnaire, i.e. any of paracetamol, Ibuprofen,

Diklofenak, acetylsalicylic acid.

### Cancer and benign breast disease

(Survey based variables at baseline in Karisma)

benign breastdisorder Benign breast disorder

breastcancer Breast cancer

othercancer Other cancer than breast

## **Cancer in family**

(Survey based variables at baseline in Karisma)

breastcancer in family nbr Number of breast cancer cases in family (1st degree

relatives, including children)

breastcancer mother Mother has breast cancer

breastcancer\_sisters Sister(s) has breast cancer, nbr

breastcancer\_daughter Daughter has breast cancer

breastcancer\_mother\_age Age at breast cancer onset for mother

breastcancer\_sister1\_age Age at breast cancer onset for (oldest) sister

breastcancer\_sister2\_age Age at breast cancer onset for (second oldest) sister

breastcancer\_in\_family Breast cancer in family (1st degree relatives, including

children)

ovariancancer in family Ovarian cancer in family (1st degree relatives, including

children)

relatives)

### **BRCA** mutation

(Survey based variable at baseline in Karisma)

brca\_mutation Gene test for BRCA mutation detection.

#### **Education**

(Survey based variable at baseline in Karisma)

education\_level Education level, see question bg5 in questionnaire for

interpretation

### **Ancestry**

(Survey based variables at baseline in Karisma)

european\_ancestry\_iso European ancestry, i.e. studyparticipant born in Europe

and parents born in Europe

born\_country Birth country of study participant

## Reproductive health

(Survey based variables at baseline in Karisma)

menarche\_age Age at menarche

cycles\_irregular Ever had irregular menstrual cycles

birth\_times Number of births

age\_at\_firstbirth Age at first child birth

unsuccessfully)

menopause status 1 = pre, 2 = peri, 3 = postmenopausal (age cut-off for

missings: pre - peri age 46, peri - post age 55)

postmenopausal Menopause due to no period in last year (age cut-off

for missings: pre - post age 50)

menopause\_age Age at menopause

hrt ever Ever used hormonal treatment

hrt status 2 = current user, 1 = previous user, 0 = never user.

Variable applies to systemic HRT use only

#### Alcohol and tobacco use

(Survey based variables at baseline in Karisma)

alcohol gram week Grams of alcohol per week (based on last year

consumption).

smoking\_packyears Number of pack years (1.0 means 20 cigarettes per day

for 1 year).

smoking\_status 2 = current user, 1 = previous user, 0 = never user

## **Quality of Life**

(Survey based variable at baseline in Karisma)

ql Overall quality of life score (QLQ-C30)

### **Sense of Coherence**

(Survey based variable at baseline in Karisma)

comprehensibility Comprehensibility means that everyday life can be

predicated, makes sense and is not confusing

manageability Manageability means that everyday life is within the

control to handled and take care of with sufficient

resources

meaningfulness Meaningfulness means that everyday life is a source of

satisfaction, being interesting and exciting, and is really

worth doing

kasam scoring is the sum of the three sub-scales

"comprehensibility", "manageability" and

"meaningfulness"

#### Karma unit

(Variables are at the time of baseline)

ipt registration date Date of study inclusion

ipt\_consent\_k2 Karisma study consent

# **FACT-ES (Functional Assessment of Cancer Therapy)**

(Survey based variables at baseline/follow-up in Karisma)

ess\_0m FACT-ES score baseline

ess 1m FACT-ES score 1 month

ess\_3m FACT-ES score 3 months

ess\_6m FACT-ES score 6 months

ess\_exit FACT-ES score exit

ess\_12m FACT-ES score 12 months

# **MMAS-8 (Morisky Medication Adherence Scales)**

(Follow-up survey based variables in Karisma)

mmas 1m MMAS score 1 month

mmas\_3m MMAS score 3 months

mmas\_6m MMAS score 6 months

mmas\_exit MMAS score exit

mmas\_12m MMAS score 12 months

# Imaging measurement of volumetric breast density

density 0m Volpara density at study entry

mammography date 0m Mammography date baseline

 mammography date 12m Mammography date 12 months

stratus pd 0m Mammographic density measurement based on Stratus

baseline

stratus\_pd\_6m Mammographic density measurement based on Stratus

6 months

stratus pd exit Mammographic density measurement based on Stratus

at date of exit examination

stratus\_pd\_12m Mammographic density measurement based on Stratus

12 months

stratus\_da\_0m Dense area (cm2) baseline

stratus\_da\_6m Dense area (cm2) 6 months

stratus\_da\_exit Dense area (cm2) exit study

stratus\_da\_12m Dense area (cm2) 12 months

cbirads\_0m Computer generated BI-RADS breast composition

classification, baseline

cbirads\_6m Computer generated BI-RADS breast composition

classification, 6 months

cbirads\_exit Computer generated BI-RADS breast composition

classification, exit

# **Analysis variables**

analysis\_itt Indication of the full population that is used for some

analyses

analysis mitt Indication of the intention to treat population

analysis pp Indication of the per-protocol analyses population

responder\_density Mammographic density responder to tamoxifen as

defined in the study protocol, i.e. median relative density decrease in the 20 mg arm in the per-protocol population at 6 months compard with baseline (-9.7%

decrease).

### Tamoxifen and metabolite concentrations

Z\_endoxifen\_ng\_mL Endoxifen (ng/mL), below detection limit = 0.05

Z\_endoxifen\_nmol\_L Endoxifen (nmol/L), below detection limit = 0.134

four\_OH\_TAM\_ng\_mL Afimoxifene (ng/mL), below detection limit = 0.1

four\_OH\_TAM\_nmol\_L Afimoxifene (nmol/L), below detection limit = 0.258

N\_DM\_TAM\_ng\_mL N-desmethyltamoxifen (ng/mL),

below detection limit = 1.0

N\_DM\_TAM\_nmol\_L N-desmethyltamoxifen (nmol/L),

below detection limit = 2.797

TAM ng mL Tamoxifen (ng/mL), below detection limit = 1.0

TAM\_nmol\_L Tamoxifen (nmol/L), below detection limit = 2.692

### CYP2D6

CYP2D6\_score Cyp2D6 gene activity score (Goetz)

https://pubmed.ncbi.nlm.nih.gov/29385237/

https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002

/cpt.1007

> 2.0 = CYP2D6 ultrarapid metabolizer

1.5 and 2.0 = CYP2D6 normal metabolizer

1.0 = CYP2D6 normal metabolizer or intermediate

metabolizer (controversy remains)

0.5 = CYP2D6 intermediate metabolizer

0 = CYP2D6 poor metabolizer

CYP2D6\_group Cyp2D6 gene activity group:

3 = CYP2D6 score > 2.0

2 = CYP2D6 score 1.5 and 2.0 1 = CYP2D6 score 0.5 and 1.0

0 = CYP2D6 score 0

### Available data sources

source sourvey Survey data available